Emily Letton | News Reporter

Articles and archive:

Analysis | Cell & Gene Therapy | Contamination Control | Design & Build | Digital | Distribution | Dosage Forms | Drug Delivery | Finance | Finished Product | Hi Tech Manufacturing | Ingredients | Logistics | Manufacturing | Marketing | Media | Microbiology | Packaging | Pharma 5.0 | Pharmaceutical | Regulatory | Research & Development | Sustainability | Training & Education

Emily covers the ever-changing pharma landscape and innovative ingredients from the supplement sector, with particular interest in sports nutrition and the policies and regulations shaping the market

Emily Letton

Profile

Emily is the Scientific Reporter for Nutraceutical Business Review and Manufacturing Chemist. Emily has a background in Biomedical Science and Genetics and a Master’s degree in Journalism from Oxford Brookes University. When she’s not reporting on the latest news, you'll find her in a boat on the river.

 

Related content

Research & Development
Amgen and AstraZeneca report positive Phase III results for Tezspire in EoE

Amgen and AstraZeneca report positive Phase III results for Tezspire in EoE

Tezspire improved swallowing symptoms and reduced oesophageal inflammation in patients with eosinophilic oesophagitis, with benefits sustained through 52 weeks, supporting its potential as a third indication
Cell & Gene Therapy
ScionxBio and Sanofi partner on long-acting mRNA therapies

ScionxBio and Sanofi partner on long-acting mRNA therapies

The collaboration will combine Sanofi’s mRNA drug candidates with ScionxBio’s AI-driven TERA platform to develop longer-lasting RNA therapeutics, potentially reducing the need for repeated administration in some medicines
Manufacturing
Recipharm adds GMP pilot-scale HPAPI suite at Leganés to bridge clinical and commercial OSD manufacturing

Recipharm adds GMP pilot-scale HPAPI suite at Leganés to bridge clinical and commercial OSD manufacturing

The dry granulation-based expansion eliminates technology transfer between development and commercial scale, with Recipharm’s ReciPredict platform reducing API consumption by up to 70% for scarce, high-cost compounds, up to OEB 5
Manufacturing
Samsung Biologics wins strike ban across nine core bioprocess stages

Samsung Biologics wins strike ban across nine core bioprocess stages

Seoul High Court has extended its injunction from three to nine manufacturing stages at Songdo, days before a planned three-week strike, with the CDMO stressing supply continuity for its global clients
Finance
Merck to acquire Silence Therapeutics in $1.3bn RNA deal

Merck to acquire Silence Therapeutics in $1.3bn RNA deal

The acquisition will add a Phase III-ready siRNA therapy for polycythaemia vera to Merck’s rare disease pipeline, strengthening the German group’s precision medicine strategy
Distribution
Cold Chain Technologies redesigns pharma shipping system to reduce dry ice use

Cold Chain Technologies redesigns pharma shipping system to reduce dry ice use

The firm has helped a global biopharma company transition from dry ice and expanded polystyrene packaging to a right-sized, paper-based thermal shipping system designed to improve sustainability and supply chain efficiency
Media
Vetter wins Red Dot Award for next-generation syringe closure

Vetter wins Red Dot Award for next-generation syringe closure

The firm's V-OVS next syringe closure system has received a Red Dot Design Concept Award, recognising design features intended to improve handling, product integrity and user experience for injectable medicines
Regulatory
MHRA seizes £2m of counterfeit weight loss pens in Birmingham raid

MHRA seizes £2m of counterfeit weight loss pens in Birmingham raid

More than 12,000 fake retatrutide and tirzepatide pens seized as regulators warn illicit GLP-1 supply chains are growing, with implications for industry
Manufacturing
Kindeva secures $226m US defence contract for nerve agent antidote autoinjectors

Kindeva secures $226m US defence contract for nerve agent antidote autoinjectors

The firm will manufacture up to 3 million ATNAA autoinjectors for the US Defense Logistics Agency to support military medical countermeasures
Research & Development
Modus Therapeutics pauses Phase II trial after unexpected serious adverse event in patient

Modus Therapeutics pauses Phase II trial after unexpected serious adverse event in patient

The Swedish biotech has voluntarily paused its Phase IIa trial of sevuparin for chronic kidney disease-associated anaemia following a suspected serious adverse reaction, delaying the proof-of-concept readout to Q1 2027 while safety data is assessed
Regulatory
ARPA-H SURPASS programme targets phaseless clinical trials

ARPA-H SURPASS programme targets phaseless clinical trials

The US agency’s SURPASS programme aims to replace sequential Phase I-III trials with continuous adaptive studies, raising questions for clinical supply and manufacturing readiness
Regulatory
Sanofi avoids EU fine as Commission accepts flu vaccine commitments

Sanofi avoids EU fine as Commission accepts flu vaccine commitments

The European Commission has accepted legally binding pledges from Sanofi to stop disparaging CSL Seqirus’ Fluad, closing an antitrust probe without a fine